Literature DB >> 17149429

The pharmacology of HIV drug resistance.

Martin M Zdanowicz1.   

Abstract

Drug resistance to human immunodeficiency virus (HIV) is a major factor in the failure of antiretroviral therapy.1 In order for practitioners to provide effective pharmaceutical care to their HIV patients, it is essential that they understand the mechanisms of HIV drug resistance as well as the various factors that can contribute to its emergence. This article is based on didactic content from the infectious disease section of the Integrated Sequence II Course in the PharmD program at South University. In the course, students are first given an overview that includes key structural components of HIV and a discussion of the HIV life cycle. A detailed presentation on the pharmacology of the various classes of antiretroviral agents follows. The clinical impact and prevalence of HIV drug resistance is then discussed along with factors that might contribute to it. Mechanisms of drug resistance for each class of antiretroviral agents are presented in detail followed by a discussion of the basis and clinical utility of HIV drug resistance testing. Finally, new targets for HIV pharmacotherapy are presented along with an overview of new antiretroviral agents that are being developed. Content taught in lecture is reinforced by relevant case studies that students work on in small groups during the recitation period.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17149429      PMCID: PMC1637011          DOI: 10.5688/aj7005100

Source DB:  PubMed          Journal:  Am J Pharm Educ        ISSN: 0002-9459            Impact factor:   2.047


  28 in total

1.  Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.

Authors:  M C Weinstein; S J Goldie; E Losina; C J Cohen; J D Baxter; H Zhang; A D Kimmel; K A Freedberg
Journal:  Ann Intern Med       Date:  2001-03-20       Impact factor: 25.391

Review 2.  HIV drug resistance and nursing practice.

Authors:  J Funesti Esch; S V Frank
Journal:  Am J Nurs       Date:  2001-06       Impact factor: 2.220

3.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

Authors:  Calvin J Cohen; Susan Hunt; Michael Sension; Charles Farthing; Marcus Conant; Susan Jacobson; Jeffrey Nadler; Werner Verbiest; Kurt Hertogs; Michael Ames; Alex R Rinehart; Neil M Graham
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

4.  Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Authors:  C Delaugerre; R Rohban; A Simon; M Mouroux; C Tricot; R Agher; J M Huraux; C Katlama; V Calvez
Journal:  J Med Virol       Date:  2001-11       Impact factor: 2.327

5.  Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors.

Authors:  Honghu Liu; Loren G Miller; Ron D Hays; Carol E Golin; Tongtong Wu; Neil S Wenger; Andrew H Kaplan
Journal:  J Acquir Immune Defic Syndr       Date:  2006-03       Impact factor: 3.731

6.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  J D Baxter; D L Mayers; D N Wentworth; J D Neaton; M L Hoover; M A Winters; S B Mannheimer; M A Thompson; D I Abrams; B J Brizz; J P Ioannidis; T C Merigan
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

7.  Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.

Authors:  O Gallego; C de Mendoza; M J Pérez-Elías; J M Guardiola; J Pedreira; D Dalmau; J Gónzalez; A Moreno; J R Arribas; A Rubio; I García-Arata; M Leal; P Domingo; V Soriano
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

8.  Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.

Authors:  U Schubert; D E Ott; E N Chertova; R Welker; U Tessmer; M F Princiotta; J R Bennink; H G Krausslich; J W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

9.  Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

Authors:  Antonella Cingolani; Andrea Antinori; Maria Gabriella Rizzo; Rita Murri; Adriana Ammassari; Francesco Baldini; Simona Di Giambenedetto; Roberto Cauda; Andrea De Luca
Journal:  AIDS       Date:  2002-02-15       Impact factor: 4.177

Review 10.  Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action.

Authors:  Muthiah Manoharan
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2002-04
View more
  12 in total

1.  The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Authors:  Vigneshwaran Namasivayam; Murugesan Vanangamudi; Victor G Kramer; Sonali Kurup; Peng Zhan; Xinyong Liu; Jacob Kongsted; Siddappa N Byrareddy
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

Review 2.  Emerging reverse transcriptase inhibitors for HIV-1 infection.

Authors:  Mohammad A Rai; Sam Pannek; Carl J Fichtenbaum
Journal:  Expert Opin Emerg Drugs       Date:  2018-05-10       Impact factor: 4.191

3.  Domain- and nucleotide-specific Rev response element regulation of feline immunodeficiency virus production.

Authors:  Hong Na; Willem Huisman; Kristofor K Ellestad; Tom R Phillips; Christopher Power
Journal:  Virology       Date:  2010-06-08       Impact factor: 3.616

4.  Integrated care of an aging HIV-infected male-to-female transgender patient.

Authors:  Pansy Ferron; Sandra Young; Catherine Boulanger; Allan Rodriguez; Jose Moreno
Journal:  J Assoc Nurses AIDS Care       Date:  2010-03-19       Impact factor: 1.354

Review 5.  Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.

Authors:  Ashley N Matthew; Florian Leidner; Gordon J Lockbaum; Mina Henes; Jacqueto Zephyr; Shurong Hou; Desaboini Nageswara Rao; Jennifer Timm; Linah N Rusere; Debra A Ragland; Janet L Paulsen; Kristina Prachanronarong; Djade I Soumana; Ellen A Nalivaika; Nese Kurt Yilmaz; Akbar Ali; Celia A Schiffer
Journal:  Chem Rev       Date:  2021-01-07       Impact factor: 60.622

6.  Nonheritable cellular variability accelerates the evolutionary processes of cancer.

Authors:  Steven A Frank; Marsha Rich Rosner
Journal:  PLoS Biol       Date:  2012-04-03       Impact factor: 8.029

7.  Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans.

Authors:  Tutsirai V Musingwini; Danai T Zhou; Doreen Mhandire; Kerina Duri; Exnevia Gomo; Olav Oktedalen; Benjamin Chimukangara; Tinei Shamu; Sandra Shawarira-Bote; Collet Dandara; Babill Stray-Pedersen
Journal:  Open Microbiol J       Date:  2017-04-28

8.  CancerDR: cancer drug resistance database.

Authors:  Rahul Kumar; Kumardeep Chaudhary; Sudheer Gupta; Harinder Singh; Shailesh Kumar; Ankur Gautam; Pallavi Kapoor; Gajendra P S Raghava
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

9.  Virtual screening models for prediction of HIV-1 RT associated RNase H inhibition.

Authors:  Vasanthanathan Poongavanam; Jacob Kongsted
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

Review 10.  Dendrimers and Dendritic Materials: From Laboratory to Medical Practice in Infectious Diseases.

Authors:  Miguel Ángel Ortega; Alberto Guzmán Merino; Oscar Fraile-Martínez; Judith Recio-Ruiz; Leonel Pekarek; Luis G Guijarro; Natalio García-Honduvilla; Melchor Álvarez-Mon; Julia Buján; Sandra García-Gallego
Journal:  Pharmaceutics       Date:  2020-09-14       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.